Almirall Aims To Disrupt Actinic Keratosis Space With Klisyri
Gel Gets Backing Of The EMA
Executive Summary
Helped by its convenient five-day dosing, the shortest of any topical treatment for the precancerous skin disease, the Spanish company believes Klisyri, already launched in the US, will become a popular alternative to current options for actinic keratosis.
You may also be interested in...
Finance Watch: Royalty Deals Pick Up As Alternative Financings Find Appeal
Public Company Edition: Seven companies revealed $2.1bn worth of royalty financings in the first quarter of 2023 and the deals keep coming in Q2, with uniQure monetizing Hemgenix royalties for up to $400m. Also, Legend grossed $350m in a follow-on offering and Athenex is liquidating via bankruptcy.
EMA Suspends Leo’s Actinic Keratosis Drug Picato
The latest drug safety actions by the European Medicines Agency affect products for dermatological use and vaginal atrophy.
Dermira’s Lebrikizumab Data Set Up Atopic Dermatitis Showdown With Dupixent
Dermira hopes to move into Phase III quickly with IL-13 inhibitor lebrikizumab, looking at monthly dosing in the maintenance setting. Efficacy in Phase IIb appears similar to Sanofi/Regeneron’s Dupixent.